Lợi Ích Của Phòng Ngừa Tiên Phát Bằng Statin: Nghiên Cứu JUPITER Phần 6 pot

Nguy cơ tim mạch ở người bệnh thận mạnHarper CR.

Tỉ lệ nữ tham gia trong các nghiên cứu

phòng ngừa tiên phát bằng statin

„ WOSCOPS: 0

„ WOSCOPS: 0

„ AFCAPS/TexCAPS: 15% (997 /6605)

„ JUPITER : 38,2% (6801 /17.802) , , ( ( ) )

JUPITER – Women Subgroup Data

Rosuvastatin Placebo

N (Rate * ) N (Rate * ) HR (95% CI) P-value

Primary endpoint** 39 (0.56) 70 (1.04) 0.54 (0.37-0.80) 0.002

Any MI 10 (0.14) 18 (0.27) 0.54 (0.25-1.18) 0.11

Any stroke 18 (0.26) 23 (0.34) 0.77 (0.42-1.42) 0.40

Arterial revascularisation 8 (0.12) 29 (0.43) 0.27 (0.12-0.59) 0.0003

A i l l i i 8 (0 12) 33 (0 49) 0 24 (0 11 0 51) 0 0001 Arterial revascularisation or

hospitalisation for unstable angina 8 (0.12) 33 (0.49) 0.24 (0.11-0.51) <0.0001

MI, stroke or CV death 36 (0.52) 48 (0.71) 0.73 (0.48-1.13) 0.16

Primary endpoint** 103 (0.88) 181 (1.54) 0.58 (0.45-0.73) <0.0001 Any MI 21 (0.18) 50 (0.42) 0.42 (0.26-0.71) 0.006

Any stroke 15 (0.13) 41 (0.34) 0.37 (0.21-0.67) 0.0005

Arterial revascularisation 63 (0.54) 102 (0.86) 0.63 (0.46-0.86) 0.003

Arterial revascularisation or

hospitalisation for unstable angina 68 (0.58) 110 (0.93) 0.63 (0.46-0.85) 0.002

MI, stroke or CV death 47 (0.40) 109 (0.92) 0.44 (0.31-0.61) <0.0001

* Rates are per 100 person-years

Mora S et al Circulation 2010; 120; 1069-1077

MI, stroke or CV death 47 (0.40) 109 (0.92) 0.44 (0.31 0.61) <0.0001

**Primary Endpoint: Time to first occurrence of a CV death, non fatal stroke, non-fatal MI, unstable angina or

arterial revascularization

Nguy cơ tim mạch ở người bệnh thận mạn

(Harper CR J Am Coll Cardiol 2008;51:2375-84)